Latest Articles
Untangling Race-based Disparities in Endometrial Cancer - Medscape
Untangling Race-based Disparities in Endometrial Cancer Medscape
Published: March 13, 2025, 8:56 a.m.
'Debilitating pain of this women's health condition left me housebound' - Glasgow Times
'Debilitating pain of this women's health condition left me housebound' Glasgow Times
Published: March 13, 2025, 6 a.m.
Breakthrough for endometriosis sufferers as first-of-its-kind pill to be available on NHS - NewsBreak
Breakthrough for endometriosis sufferers as first-of-its-kind pill to be available on NHS NewsBreak
Published: March 13, 2025, 5:37 a.m.
Breakthrough for endometriosis sufferers as first-of-its-kind pill to be available on NHS - newsbreak.com
Breakthrough for endometriosis sufferers as first-of-its-kind pill to be available on NHS newsbreak.com
Published: March 13, 2025, 5:37 a.m.
Breakthrough for endometriosis sufferers as new pill to be available on NHS - The Independent
Breakthrough for endometriosis sufferers as new pill to be available on NHS The Independent
Published: March 13, 2025, 5:37 a.m.
Kerry hotel plays host to second annual Cneasu Endometriosis Inspired Women’s Health Retreat - Irish Independent
Kerry hotel plays host to second annual Cneasu Endometriosis Inspired Women’s Health Retreat Irish Independent
Published: March 13, 2025, 4 a.m.
'First-of-a-kind' endometriosis tablet approved for use on NHS - This is the Coast
'First-of-a-kind' endometriosis tablet approved for use on NHS This is the Coast
Published: March 13, 2025, 3:01 a.m.
Breakthrough for endometriosis sufferers as first-of-its-kind pill to be available on NHS - MSN
Breakthrough for endometriosis sufferers as first-of-its-kind pill to be available on NHS MSN
Published: March 13, 2025, 1:21 a.m.
Association Between Levonorgestrel-Releasing Intrauterine System Exposure Duration and Breast Cancer Incidence.
To investigate the association between the duration of levonorgestrel-releasing intrauterine system (LNG-IUS) use and breast cancer risk in Korean women.
Published: March 13, 2025, midnight
Dydrogesterone is an eligible tool to suppress LH surge in assisted reproduction technologies (ART) cycles.
To evaluate Dydrogesterone's effectiveness in PPOS protocols for IVF/ICSI or oocyte cryopreservation, focusing on LH surge suppression and metaphase II oocyte yield.
Published: March 13, 2025, midnight
Link copied to clipboard!